RecruitingPhase 1Phase 2NCT06481306
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470
Sponsor
Bristol-Myers Squibb
Enrollment
184 participants
Start Date
Jul 17, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria13
- \- Cohort A.
- i) Healthy male and female (who are not of childbearing potential) participants, as determined by the investigator based on medical history and other determinations. Females not of childbearing potential must have been amenorrhoeic for at least 12 months without an alternative medical cause and have follicle-stimulating hormone (FSH) levels of at least 40 IU/L or have undergone a hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
- ii) Body mass index (BMI) of 18.0 to 32.0 kg/m\^2, inclusive. BMI = weight (kg)/ (height \[m\])\^2 as measured at screening.
- iii) No evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory assessments beyond what is consistent with the target population.
- \- Cohort B.
- i) Participants with a documented diagnosis of Sickle Cell Disease (SCD) with genotype HbSS, HbSβ0-thal, or HbSβ+-thal.
- ii) Participants with ≥ 4 vaso-occlusive crises (VOCs) within the previous 12 months or ≥ 2 VOCs within the previous 6 months.
- iii) Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- iv) Must have the following laboratory values:.
- A. Hemoglobin ≥ 5.5 and ≤ 12 g/dL (males) or ≥ 5.5 and ≤ 10.6 g/dL (females).
- B. Absolute neutrophil count ≥ 1500/μL.
- C. Platelet count ≥ 100 × 10\^3/μL.
- D. Absolute reticulocyte count \> 100 × 10\^3/μL or \> 50 × 10\^3/μL if taking hydroxyurea.
Exclusion Criteria11
- \- Cohort A.
- i) Any significant medical condition or any condition that confounds the ability to interpret data from the study.
- ii) Participant has any condition, including the presence of laboratory abnormalities, that places the participant at unacceptable risk if the participant was to participate in the study.
- iii) Any major surgery or planned surgery (except GI surgery) within 12 weeks of the first study intervention administration.
- \- Cohort B.
- i) Participants with any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.
- ii) Participants with more than 6 severe VOCs defined as VOCs requiring ≥ 24 hours of hospital admission within 12 months prior to the first dose of study intervention or any VOC requiring ≥ 24 hours of hospital admission within 30 days prior to the first dose of study intervention.
- iii) Participants with any episode of acute chest syndrome within the last 6 months prior to the first dose of study intervention.
- iv) Creatinine clearance (CrCl) \< 60 mL/min/1.72m2 using Chronic Kidney Disease Epidemiology (CKD-EPI) equation
- Cohort A and B.
- i) Participant is receiving regularly scheduled RBC or platelet transfusions or has received a RBC transfusion within 28 days and a platelet transfusion within 14 days prior to starting treatment with BMS-986470.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBMS-986470
Specified dose on specified days
DRUGPlacebo
Specified dose on specified days
DRUGFamotidine
Specified dose on specified days
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06481306
Related Trials
Evaluation of Patients With Mood and Anxiety Disorders and Healthy Volunteers
NCT000246351 location
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT023794291 location
A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants
NCT073299722 locations
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
NCT0711889110 locations
Physical and Behavioral Traits of Overweight and Obese Adults
NCT004289871 location